Navigation Links
Kuros Announces Allowance of US Patent for the Local Application of Parathyroid Hormone (PTH) for Bone Healing
Date:7/18/2011

ZURICH, July 19, 2011 /PRNewswire/ --


 

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office. The now allowed application acknowledges that Kuros has been first in showing that parathyroid hormone (PTH) when applied locally in a matrix to a bone defect has the ability to improve bone healing. Kuros has already demonstrated the clinical utility of this proprietary approach to bone healing in two large phase II studies in trauma patients which have reported previously.

Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The Company's product candidates are based on two different matrix technology platforms.  Kuros' most advanced products are based on a fibrin matrix and include KUR-111 and KUR-113 which have achieved positive results in large Phase II trials for tibial plateau fractures and tibial shaft fractures respectively.

 Didier Cowling, Chief Executive Officer at Kuros says: "This patent will give Kuros broad protection on the concept of locally applied PTH to improve bone healing. Obtaining the notice of allowance for this US patent application further builds on Kuros' proprietary position in local treatments for bone generation and healing".

The Notice of Allowance for US 11/679,807 with its broad scope of protection follows US 7,247,609, US 6,331,422, US 6,607,740, EP 1 465 989, EP 1 124 590, EP 1 280 566 and patents in many other countries which protect Kuros` approach with PTH and its incorporation into matrices for local therapeutic applications.

About Kuros

http://www.kuros.ch

Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications.

Kuros has two biomaterial technology platforms, one based on fibrin sealants and the other based on its own proprietary synthetic technology that can mimic fibrin in many of its attributes.  These materials can be used alone or in combination with biologically active molecules.

Kuros' combination products are designed to mimic the body's natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecules into the injectable matrices aims to maximize their activity by retention at the site of action. Kuros products are designed to combine ease of application with localized delivery.  Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules.

Kuros' has a diverse pipeline of product candidates with its most advanced product candidates being in trauma and wound care.

Since its creation, Kuros has raised over $150 million. The company is located in Zurich, Switzerland.

Press Enquiries

Kuros
Didier Cowling, CEO +41(0)44-200-56-62
Alistair Irvine, Director of Business Development +41(0)44-200-56-62

For Swiss Media Enquires:
IRF Communications
Martin Meier-Pfister +41(0)43-244-81-40
Jan Gregor +41(0)43-244-81-54

For International Media Enquires:
Citigate Dewe Rogerson
David Dible, Nina Enegren +44(0)207-638-9571



'/>"/>
SOURCE Kuros Biosurgery AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):